Konstantin Karmazin, MD

Konstantin Karmazin, MD, clinical neurologist and chief medical officer of Prime PD

Articles by Konstantin Karmazin, MD

Konstantin Karmazin, MD, clinical neurologist, CMO, Prime PD

Future Plans, Goals for Prime PD: Konstantin Karmazin, MD

February 14th 2022

The chief medical officer of Prime PD, a new digital wellness studio for patients with Parkinson disease, detailed future initiatives for the platform. [WATCH TIME: 4 minutes]

Creating Community and Convenience With Prime PD: Konstantin Karmazin, MD

ByKonstantin Karmazin, MD

February 13th 2022

The CMO of the digital wellness studio detailed the positive feedback received thus far from patients with Parkinson disease. [WATCH TIME: 6 minutes]

Konstantin Karmazin, clinical neurologist, CMO, Prime PD

What Clinicians Need to Know About Prime PD: Konstantin Karmazin, MD

ByKonstantin Karmazin, MD

February 11th 2022

The CMO of the digital wellness studio spoke on the options to personalize training curricula for patients with Parkinson disease. [WATCH TIME: 4 minutes]

Konstantin Karmzain, MD, clinical neurologist, and CMO, Prime PD

Prime PD: A New Virtual Fitness Program for Parkinson Disease: Konstantin Karmazin, MD

ByKonstantin Karmazin, MD

February 10th 2022

The chief medical officer of Prime PD spoke on motivations behind the development of the program and the unique benefits it offers amidst the ongoing COVID-19 pandemic. [WATCH TIME: 3 minutes]

Konstantin Karmazin, MD

Articles by Konstantin Karmazin, MD

Future Plans, Goals for Prime PD: Konstantin Karmazin, MD

Creating Community and Convenience With Prime PD: Konstantin Karmazin, MD

What Clinicians Need to Know About Prime PD: Konstantin Karmazin, MD

Prime PD: A New Virtual Fitness Program for Parkinson Disease: Konstantin Karmazin, MD

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Mechanism and Long-Term Outlook of Zeleciment Rosturdirsen in Treating Duchenne Muscular Dystrophy: Doug Kerr, MD, PhD

Clene to Submit Application for CNM-Au8 as Potential ALS Treatment

Targeting Myasthenia Gravis at the Source: Promising Progress of CAR-T Agent KYV-101

NeuroVoices: Tanya Simuni, MD, FAAN, on Emerging Directions in Disease-Modifying Therapy Trials for Parkinson Disease

Study Forecasts Uptick in ALS Prevalence in Coming Decades